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Abstract: We investigated the role of ERK1/2 in the brain on the effects of centrally administered resistin on ther-
mogenesis. Resistin (7 µg) into anaesthetized rats significantly decreased brown adipose tissue temperature by 1.0 
± 0.4 °C (P < 0.005). This response was significantly attenuated by over 60% when ERK1/2 was inhibited by U0126 
(7 µg) (P < 0.05). Resistin reduced uncoupling protein-1 mRNA expression (0.11 ± 0.01 vs 1.24 ± 0.85 resistin vs 
control respectively) and the expression of peroxisome proliferator-activated receptor gamma co-activator 1-α, but 
the effects were not statistically significant. The results suggest that ERK1/2 in the brain contributes to resistin’s 
effects on thermogenesis. 
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Introduction
Resistin is a newly discovered adipokine origi-
nally identified in adipose tissue [1], but now 
known to be expressed in a variety of tissues, 
including the hypothalamus in the brain [2, 3]. 
Resistin belongs to a family of cysteine-rich 
proteins capable of inducing insulin resistance 
and affecting energy metabolism [4]. Plasma 
levels of resistin are high in conditions like obe-
sity, a condition in which there is an imbalance 
between energy intake and expenditure. 
Resistin has been shown to reduce dietary 
intake, thereby reducing energy intake [5]. 
Energy expenditure is regulated by basal meta-
bolic rate, physical activity and thermogenesis. 
Brown adipose tissue (BAT) is a key organ 
responsible for non-shivering thermogenesis, 
thereby influencing energy dissipation [6]. This 
function is linked to the unique presence of 
uncoupling protein-1 (UCP1) on the inner mito-
chondrial membrane of brown adipocytes. 
UCP1 ‘uncouples’ fuel oxidation from adenos-
ine triphosphate synthesis resulting in dissipa-
tion of considerable energy as heat [6] and 
increased BAT and body core temperatures. 
The thermogenic function of BAT is tightly regu-
lated by the sympathetic nervous system 
through activation of adrenoreceptors that elicit 
changes in UCP1 and other important thermo-
genic proteins, such as the transcriptional co-
activator peroxisome proliferator-activated 
receptor gamma co-activator 1-α (PGC-1α) [7]. 
Resistin reduces sympathetic nerve activity 
innervating BAT, an effect mediated by 
Extracellular Regulated kinases 1/2 (ERK1/2) 
in the brain [10]. ERK1/2 are a family of cellular 
protein kinase enzymes involved in diverse cel-
lular functions including cell growth, prolifera-
tion and neuronal activity. ERK1/2 has also 
been found to mediate the actions of resistin 
on cell proliferation, migration and hypertrophy 
[8, 9]. Thus, in the present study, we investigat-
ed whether ERK1/2 in the brain mediates resis-
tin’s effects on BAT temperature and body core 
temperature, and whether centrally adminis-
tered resistin affected the mRNA expression of 
UCP1 and PGC-1α via brain ERK1/2. 
Methods
Animals 
All experiments were performed in accordance 
with the Prevention of Cruelty to Animals Act 
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1986 (Australia). They conformed with the 
Guiding Principles for Research Involving 
Animals and Human Beings (2) and guidelines 
set by the Australian Code of Practice for the 
Care and Use of Animals for Scientific Purposes, 
2007 (National Health and Medical Research 
Council of Australia). Experiments were 
approved by the Royal Melbourne Institute of 
Technology (RMIT) University Animal Ethics 
Committee. 
Male Sprague Dawley rats were obtained from 
ARC animal resources centre (Western 
Australia). Rats were housed at 23 °C with a 
12-h light/dark cycle and given free access to 
standard rat chow and water.
Procedures
General
Rats were fasted overnight before an experi-
ment. On the day of the experiment, anaesthe-
sia was induced using isoflurane gas (2.5–3%) 
in O2. A catheter was inserted into the femoral 
vein, to maintain anaesthesia with intravenous 
urethane (1–1.4 g/kg initially, followed by sup-
plemental doses of 0.05 g/kg as required). The 
depth of anaesthesia was maintained to ensure 
the absence of corneal and pedal reflexes. 
BAT temperature and body core temperature 
recording: The interscapular BAT was exposed 
and the tip of a thermistor probe was inserted 
into it to measure temperature (Fluke 73III, 
Fluke Australia, NSW, Australia). Body core tem-
perature was measured by a thermometer 
placed in the rectum (Fluke 52II thermometer, 
Fluke Australia, NSW, Australia).
Microinjections into the lateral brain ventricle
Each animal was placed prone and its head 
was mounted in a Stoelting stereotaxic frame, 
such that bregma and lambda were on the 
same horizontal plane. A hole (4 mm diameter) 
centred 0.7 mm caudal and 1.8 mm lateral 
from bregma, was drilled into the skull. The 
hole was covered with cotton wool soaked in 
normal saline to cover the brain surface.
Intracerebroventricular (ICV) microinjections 
were made unilaterally using a fine glass micro-
pipette (50–70 µm tip outer diameter) inserted 
into the lateral brain ventricle (stereotaxic coor-
dinates: 0.7 mm caudal to bregma, 1.8 mm lat-
eral to midline, and 3.7 mm ventral to the sur-
face of the dura). After the ICV injections, the 
micropipette was left in place for 1 min. At the 
end of the experiment, a small amount of pon-
tamine sky blue was microinjected using the 
same coordinates, to confirm injection into the 
lateral ventricle. 
Experimental protocols
Resting levels of BAT and body core tempera-
tures were recorded for at least 10 min before 
ICV injections. Temperature changes were mon-
itored for 3–4 hr after ICV injection of resistin 
(7 µg in 5 µL) in rats pre-treated with the 
ERK1/2 inhibitor U0126 (7 µg in 2 µL, n=5) 
(administered 20–30 min earlier) or vehicle 
(DMSO, n=8). In separate groups, vehicle (n=7) 
or U0126 (n=5) were administered following 
pretreatment with artificial cerebrospinal fluid. 
Artificial cerebrospinal fluid contained NaCl 
124 mM, KCl 3.0 mM, NaH2PO4.2H2O 1.3 mM, 
MgCl2.6H2O 2.0 mM, NaHCO3 26 mM, glucose 
10 mM, CaCl2 2.0 mM in Milli-Q water, buffered 
with carbogen.Recombinant rat resistin (lot#- 
L16251/F) and U0126 (lot#3-Z5175W) were 
purchased from Sapphire Biosciences (Aus- 
tralia). DMSO (lot#109K2350) was obtained 
from Sigma (Australia).
BAT sampling and processing
Animals were euthanized 3–4 hr after ICV injec-
tions. BAT was rapidly excised, frozen in liquid 
nitrogen and stored at –80 °C for subsequent 
RNA extraction.
RNA extraction and quantification: BAT RNA 
extraction was performed using a TRIzol-based 
kit, following the manufacturer’s directions 
(Invitrogen, Melbourne, Australia, Cat No 
12183-018A). Briefly, around 30 mg of BAT was 
put in 500 µL of TRIzol and homogenised with a 
handheld, motorised Teflon pestle. After elution 
through a spin cartridge, extracted RNA was 
quantified using a QUANT-iT analyzer kit 
(Invitrogen, Melbourne, Australia, Cat No 
Q32852), following the manufacturer’s direc-
tions. RNA samples were diluted as appropriate 
to equalise concentrations, and stored at minus 
80 °C for subsequent reverse transcription.
Reverse transcription and real-time quantita-
tive polymerase chain reaction (RT-PCR): First-
strand complementary DNA (cDNA) synthesis 
was done using commercially available TaqMan 
Reverse Transcription Reagents (Invitrogen, 
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Melbourne, Australia) in a final reaction volume 
of 20 µL. All RNA and negative control samples 
were reverse transcribed to cDNA in a single 
run from the same reverse transcription master 
mix. A serially diluted pooled RNA sample from 
the control group was produced and included 
to make sure reverse transcription was efficient 
and calculate a standard curve for RT-PCR. 
Quantification of mRNA (in duplicate) was per-
formed on a 72-well Rotor-Gene 3000 
Centrifugal Real-Time Cycler (Corbett Research, 
Mortlake, Australia). Taqman-FAM-labelled pri- 
mer/probes for UCP1 (Cat No. Rn 00562126_
m1) and PGC-1α (Cat No. Rn00580241_m1) 
were used in a final reaction volume of 20 µL. 
PCR conditions were 2 min at 50 °C, 10 min at 
95 °C, then 40 cycles at 95 °C for 15 s and 60 
°C for 60 s.
Statistical analysis 
BAT and body core temperatures: Resting lev-
els of BAT and body core temperatures before 
Figure 1. Bar graph shows brown adipose tissue temperature (Tbat) and body core temperature (Tcore) before 
intracerebroventricular administration of resistin alone (7 µg, n=7 for Tbat, n=8 for Tcore), resistin in the presence 
of U0126 (7 µg in 2 µL, n=5), U0126 alone (n=6) or vehicle (Control, n=8). Changes in Tbat and Tcore from resting 
levels over time in response to treatment are shown in the right panels. *p < 0.05, resistin alone vs resistin in the 
presence of U0126. **p < 0.005, resistin alone vs control.
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the injections were compared between groups 
using one-way ANOVA. When a significant dif-
ference was observed, comparisons between 
groups were made using Tukey’s post-hoc test. 
Changes from resting levels of BAT and body 
core temperatures were compared between 
groups in each experimental series using two-
way ANOVA with repeated measures. All results 
are expressed as means ± SE. P < 0.05 was 
considered to be statistically significant.
mRNA expression: 18 S ribosomal RNA (18 S 
rRNA) (Cat No. Hs99999901_s1) was used as 
a housekeeping gene to normalize threshold 
cycle (CT) values. The relative amounts of 
mRNAs were calculated using the relative quan-
tification (∆∆CT) method [11]. Values were 
expressed relative to 18 S ribosomal RNA and 
presented in arbitrary units. Comparisons 
between the groups were performed using a 
one-way ANOVA. When a significant difference 
was observed, comparisons between groups 
were made using Tukey’s post-hoc test. Due to 
technical problems, mRNA levels could not be 
measured in BAT from all animals. All results 
are expressed as means ± SE. P < 0.05 was 
considered to be statistically significant.
Results
BAT and body core temperatures and the ef-
fects of ERK1/2 inhibition 
Resting levels of BAT and body core tempera-
tures before ICV injection of the drugs are 
shown in Figure 1. Compared with the control 
group, there was a small but statistically signifi-
cant difference in resting BAT temperature in 
groups that received resistin. Resting body core 
temperatures before ICV injection of resistin 
were not different between the groups (Figure 
1). 
ICV injection of resistin markedly reduced both 
BAT temperature (P < 0.005) and body core 
temperatures (Figure 1). In rats pre-treated 
with the ERK1/2 inhibitor, U0126, resistin’s 
effect on BAT temperature was significantly 
attenuated by over 60% (P < 0.05) (Figure 1). 
U0126 alone did not significantly change BAT 
temperature (Figure 1). Resistin decreased 
body core temperature by 1.09 ± 0.44 °C from 
resting levels, and although U0126 attenuated 
this effect by over 60%, the reduction did not 
reach statistical significance (Figure 1).
mRNA expression: UCP, PGC-1α
UCP1 mRNA expression was lower in the resis-
tin-treated group (0.11 ± 0.01) than in the con-
trol group (1.24 ± 0.85), but this difference was 
not statistically significant. Inhibiting ERK1/2 in 
the brain blunted resistin’s effect on UCP1 
expression, however, this effect was not statis-
tically significant (Figure 2A). Figure 2B shows 
the levels of mRNA expression for PGC-1α in 
BAT. There were no statistically significant dif-
ferences in PGC-1α expression between 
groups.
Figure 2. A: UCP1 and (B) PGC-1α mRNA abundance in BAT from control (n=4 for UCP1, n=6 for PGC-1α), resistin 
(n=5), U0126 (ERK1/2 inhibitor) + resistin (n=4) and U0126 (n=3) groups. Values are expressed relative to 18 S 
ribosomal RNA and presented in arbitrary units (mean ± SEM). 
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Discussion
This study reports that acute injections of resis-
tin into the lateral ventricle of the brain mark-
edly decreased BAT temperature and the 
response was significantly attenuated when 
central ERK1/2 was inhibited by U0126. We 
note that the resting BAT temperatures in the 
resistin group and in the U0126+resistin group 
were significantly greater than control. 
Although, one could argue that the fall in BAT 
temperature may be due to the higher basal 
level readjusting down to a lower level, it is 
more difficult to reconcile the fact that the 
reduction induced by resistin was significantly 
greater than that in the U0126+resistin group, 
as the latter group had a higher basal level. It is 
also noteworthy that we have shown previously 
that resistin significantly reduced BAT sympa-
thetic nerve activity, a direct measure of 
thermogenesis. 
The fall in BAT temperature was most likely 
responsible for the resistin-induced decrease 
in body core temperature. When central 
ERK1/2 was inhibited, the decrease in body 
core temperature induced by resistin was 
blunted (in excess of 60%) but the effect was 
not statistically significant, probably due to the 
variance seen in the control group. Nonetheless, 
the findings are in agreement with previous 
reports showing that central resistin reduces 
BAT sympathetic nerve activity [12], and that 
effect was mediated by central ERK1/2. It is 
not likely that a reduction in body core tempera-
ture was responsible for the fall in BAT temper-
ature since (i) a reduction in body core temper-
ature should reflexly increase BAT temperature, 
and (ii) resistin significantly lowered BAT sym-
pathetic nerve activity when body core temper-
ature was carefully maintained constant [12].
In contrast to resistin, leptin has been shown to 
increase BAT thermogenesis by increasing the 
BAT sympathetic nerve activity [13]. Interes- 
tingly, central ERK1/2 mediated the action of 
central leptin on BAT sympathetic nerve activity 
[14]. Together, the results suggest that central 
ERK1/2 signalling pathways are involved in the 
resistin-induced decrease in BAT thermogene-
sis and the leptin-induced increase in BAT ther-
mogenesis. Given the two adipokines have 
opposing actions on thermogenesis, it seems 
likely that different cell groups mediate those 
actions.
In the present study, the average UCP1 mRNA 
expression was lower in the resistin-treated 
group than in the control group and this 
response was blunted when central ERK1/2 
signalling pathways were inhibited. Although 
these changes were not statistically significant, 
the data are consistent with the findings that 
resistin reduces BAT temperature. There is con-
siderable evidence indicating the presence of 
metabolically active BAT in adult humans [15, 
16], and it has been recently demonstrated 
that ablation of UCP1 induced obesity in mice 
fed a control diet under thermoneutral condi-
tions [17]. The effects of resistin observed in 
the present study is consistent with reduced 
thermogenic capacity and energy expenditure 
and suggest furtile ground for further study on 
novel mechanisms to tackle obesity. 
PGC-1α belongs to a family of nuclear transcrip-
tional cofactors that regulate mitochondrial bio-
genesis and is involved in the regulation of 
brown adipocyte-specific genes [18]. PGC-1α is 
believed to control UCP1 expression, although 
this is controversial since studies have shown 
that PGC-1α and UCP1 gene expression in 
brown adipocytes are not necessarily correlat-
ed [19, 20]. Our current study showed the aver-
age amount of PGC-1α mRNA was lower in the 
resistin-treated group than in the control group, 
but this was not statistically significant. 
Nonetheless, it is noteworthy that the expres-
sion pattern of PGC-1α in the different treat-
ment groups followed the same expression pat-
tern as UCP1. 
In conclusion, the main finding of this study 
highlights the importance of ERK1/2 signalling 
pathways in the brain in mediating the reduc-
tion in BAT thermogenesis induced by resistin. 
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